Abstract. Lewy bodies (LBs) containing ␣-synuclein (␣SYN) fibrils are the hallmark lesions of Parkinson disease, dementia with LBs, and related neurodegenerative diseases. Here we have investigated the susceptibility to proteolysis of ␣SYN from brain samples of patients with different subtypes of LB diseases. While soluble ␣SYN was completely degradable in all samples, the affected brain regions additionally contained insoluble, proteinase K (PK)-resistant ␣SYN. In brainstem-predominant subtype LB disease cases, PK-resistant ␣SYN was found in the medulla and substantia nigra, but not in cerebral cortex. In limbic subtype LB disease cases, PK resistance of ␣SYN spread to the cingulate and parahippocampal cortex, and further to the frontal cortex in neocortical subtype LB disease cases. Variable amounts of neuritic PK-resistant ␣SYN were found in the striatum of all cases. Thus, PK resistance of ␣SYN may be useful for the development of biomarkers of LB diseases.
INTRODUCTION
␣-Synuclein (␣SYN) is a synaptic protein that is abundantly expressed in brain. ␣SYN is normally transported very efficiently to the synapse, where it regulates the mobilization of synaptic vesicles (1) . The molecular mechanism of the physiological function of ␣SYN remains to be elucidated. Pathologically, ␣SYN has a propensity to form aggregates, which is enhanced by risk factors for Parkinson disease (PD), including mutations, hyperphosphorylation, oxidation, metal ions, and pesticides (2) (3) (4) (5) (6) . Transgenic ␣SYN aggregates in vivo and causes neurodegeneration in Drosophila (7) and mouse models (8) (9) (10) (11) (12) (13) .
The deposition of fibrillar ␣SYN aggregates in neuronal perikarya (i.e. Lewy bodies [LBs] ) and in Lewy neurites (LNs) is characteristic of PD, dementia with LBs, LB variant Alzheimer disease, neurodegeneration with brain iron accumulation type 1 (formerly Hallervorden-Spatz disease), and pure autonomic failure (14) (15) (16) (17) (18) . Moreover, oligodendroglial as well as neuronal cytoplasmic inclusions are characteristic of multiple system atrophy (19) (20) (21) . These diseases are collectively referred to as ␣-synucleinopathies (22, 23) .
LB pathology can be classified into brainstem-predominant, limbic (transitional), and neocortical subtypes PK resistance of ␣SYN in brainstem-type LB disease cases. A: Frozen samples from medulla, striatum, cingulate cortex, parahippocampal cortex (paraHC), and frontal cortex were fractionated into sarcosyl extracts (upper panel) and soluble material (lower panel), and incubated without (Ϫ) or with (ϩ) 3 g/ml PK. Western blots were probed with monoclonal 15G7 anti-␣SYN, revealing monomers (␣SYN) 1 , dimers (␣SYN) 2 , and oligomers/aggregates (␣SYN) n . Positions of molecular weight standards are indicated to the right. B-G: PK-PET blots with monoclonal 15G7 anti-␣SYN antibody. Abundant PK-resistant ␣SYN was detected in the medulla (B), the substantia nigra (C), and the striatum (D). Only single neurites were detectable in the entorhinal cortex of the parahippocampal gyrus (F), whereas the cingulate (E) and frontal cortex (G) showed no labeling. Scale bar in (B) corresponds to 1 mm. Scale bar in (C) corresponds to 250 m (C-G) and 100 m in inserts in (D) and (F). Data shown are from case 3.
Western Blot Analysis
Frozen tissue was fractionated and PK-digested as described previously (12, 33) . Half a gram of tissue was homogenized at 4ЊC in 5 vol (w/v) buffer A (50 mM Tris (pH 7.5), 1 mM EGTA, 1 mM dithiothreitol) using a mechanical Teflon potter, and centrifuged for 10 min at 1,000ϫg. The resulting postnuclear supernatant was centrifuged for 20 min at 350,000ϫg. The high-speed supernatant (''soluble fraction'') was retained for PK digestion (see below). The high-speed pellet was resuspended in 10 vol (w/v) buffer A ϩ 1% Triton X-100. After 20 min centrifugation at 350,000ϫg, the pellet was resuspended in buffer A ϩ 0.5 M NaCl and 10% sucrose. After another 20 min centrifugation at 350,000ϫg, the pellet was resuspended in buffer A ϩ 0.5 M NaCl, 10% sucrose, 1% sarcosyl, and incubated for 1 hour at 37ЊC. The resulting sarcosyl extract was cleared by 20 min centrifugation at 27,000ϫg, and the supernatant (''sarcosyl fraction'') retained for PK digestion.
Total protein concentration was measured using the BCA Protein Assay (Pierce, Rockford, IL). Soluble fractions (25 g protein adjusted to 30 l) and sarcosyl fractions (1 mg protein adjusted to approximately 0.5 ml) were incubated without or with PK (Qiagen, Hilden, Germany) for 30 min at 37ЊC. Reactions were stopped by the addition of SDS-PAGE sample buffer, boiled for 5 min, quick-spun, and loaded onto denaturing 15% polyacrylamide gels. After electrophoresis, proteins were electro-blotted on polyvinylidene fluoride membranes (0.45 m Immobilon-P, Millipore, Billerica, MA). Western blots were blocked with 5% skimmed milk and probed with ␣SYN-specific 15G7 hybridoma supernatant (34) (1:5 in milk) followed by horseradish peroxidase-conjugated anti-rabbit and anti-rat IgG, respectively, 1:5,000 in milk (Sigma-Aldrich, St. Louis, MO). Immunoreactive bands were visualized by enhanced chemiluminescence (ECLplus, Amersham Biosciences, Uppsala, Sweden) on SuperRX film (Fuji, Dusseldorf, Germany). For semiquantitative comparison of band intensities, exposure times were normalized to equal signals originating from 20 ng purified recombinant ␣SYN (prepared as described (35) ) loaded as marker on every Western blot.
PK-Digested Paraffin-Embedded Tissue Blot Analysis
The PK-digested paraffin-embedded tissue (PK-PET) blot was performed as described previously. Briefly, 5 m sections from paraffin-embedded tissue were cut on a microtome, placed in a water bath (55ЊC), collected on a wet 0.45 m nitrocellulose membrane (Bio-Rad Laboratories, Hercules, CA), and dried for at least 8 hours at 55ЊC. The section on the nitrocellulose membrane was deparaffinized with xylene and rehydrated using a descending ethanol series. After wetting with TBS-T (10 mM Tris-HCl, pH 7.8; 100 mM NaCl; 0.05% Tween-20), digestion was performed with 50 g/ml PK (Roche Diagnostics, Mannheim, Germany) in TBS-B (10 mM Tris-HCl, pH 7.8; 100 mM NaCl; 0.1% Brij-35) for 8 to 14 hours at 55ЊC. After washing 3 times with TBS-T, the proteins on the membranes were Figure  1A . B-G: PK-PET blots with monoclonal 15G7 anti-␣SYN antibody. Numerous neuritic profiles and LBs were labeled in the medulla (B), the substantia nigra (C), and the striatum (D). Predominant neuritic pathology and single LBs were revealed in the cingulate (E) and parahippocampal gyrus (F). No labeling was seen in the frontal cortex (G). Scale bar in (B) corresponds to 1 mm. Scale bar in (C) corresponds to 250 m (C-G) and 100 m in insert in (D). Data shown are from case 6. denatured with 3 M guanidine isothiocyanate in 10 mM TrisHCl (pH 7.8) for 10 min. After preincubation in blocking solution (0.2% casein in TBS-T) for 30 min, immunostaining was performed with monoclonal 15G7 anti-␣SYN (dilution 1:50) for 8 hours at 4ЊC. After incubation with a bridging rabbit anti-rat antibody (dilution 1:500, DakoCytomation, Hamburg, Germany) in the case of 15G7, incubation for at least 1 hour was performed with an alkaline phosphatase coupled goat-anti rabbit or goat-anti-mouse antibody (dilution 1:500; DakoCytomation), respectively. After 5 washes in TBS-T for 10 min, the membranes were adjusted to alkaline pH by incubating 2 times for 5 min in NTM (100 mM Tris-HCl, pH 9.5; 100 mM NaCl; 50 mM MgCl 2 ). The visualization of the antibody reaction was provided by formazan reaction using NBT/BCIP. Blots were evaluated with an Olympus dissecting microscope. In all cases, the following regions were examined by the PK-PET blot method: medulla, substantia nigra, cingulate gyrus, parahippocampal gyrus, and middle frontal gyrus.
Statistical Analysis
The signal intensities of PK-resistant ␣SYN on Western blots and PET blots were ranked as follows: 0, none; 0.5, faint; 1, weak; 2, moderate; 3, strong. Both parameters were plotted against each other and against LB counts determined by standard immunohistochemistry, and subjected to linear regression analysis. Statistical significance of linear correlation was calculated by ANOVA using StatView 4.5 software (Abacus Concepts, Inc., Berkeley, CA).
RESULTS

Brainstem-Predominant LB Disease
Cerebral brain samples contained abundant ␣SYN in the soluble fractions. Soluble ␣SYN was monomeric and completely PK-digested under these conditions (Fig. 1A) . Medullary ␣SYN levels were consistently lower than those in cerebrum. ␣SYN in the soluble medullary fractions was also readily degraded upon PK digestion (Fig.  1A) . ␣SYN was detectable in the sarcosyl fractions prepared from brainstem-type LB disease patients (Fig. 1A) , but close to the detection limit. The striatum that receives projections from the LB-containing substantia nigra also showed signs of ␣-synucleinopathy. Sarcosyl fractions from the striatum of brainstem-type LB disease patients contained variable amounts of ␣SYN. The molecular mass of the ␣SYN bands is consistent with the presence of ␣SYN monomers, dimers, and oligomers/aggregates (Fig. 1A) . All of these sarcosyl-extracted ␣SYN species were resistant to PK. Cortical samples tended to contain very little, if any, ␣SYN in the sarcosyl fractions. The example shown in Figure 1 (case 3) appears to represent a patient in whom LB pathology was about to spread into the parahippocampal cortex, because there were traces of ␣SYN in the sarcosyl fraction from the parahippocampal cortex of this individual.
To analyze the distribution of PK-resistant ␣SYN in greater detail, we performed PK-PET blotting of the contralateral hemispheres from the same patients (Fig. 1B-G) . The cases with the brainstem-predominant LB pathology showed abundant labeling in the dorsal motor nucleus of the glossopharyngeal and vagal nerve, the intermediate reticular zone, and the caudal raphe nuclei in the medulla (Fig. 1B) as well as in the substantia nigra pars compacta (Fig. 1C) . Higher magnification revealed numerous neuritic profiles and to a lesser degree LBs in these regions. Moreover, the PK-PET blot allowed the detection of a massive striatal ␣-synucleinopathy with labeling of numerous neurites, grain-like aggregates and a few LBs (Fig. 1D) . The examined limbic and neocortical regions were devoid of PK-resistant ␣SYN (Fig. 1E-G) , with the exception of case 3, where a few positive neurites were labeled in the entorhinal cortex (Fig. 1F ).
Limbic-Type LB Disease
The properties of medullary and striatal samples from limbic-type DLB patients were similar to those from brainstem-type LB disease patients. Again, ␣SYN in the soluble fractions was monomeric and fully PK-labile, with relatively low expression of ␣SYN in the medulla ( Fig. 2A) . As was seen in brainstem-type LB disease patients (Fig. 1A) , both medulla and striatum contained ␣SYN monomers, dimers, and oligomers/aggregates in the sarcosyl fractions prepared from limbic-type LB disease patients (Fig. 2A) . All these ␣SYN species were resistant to PK (Fig. 2A) . In contrast to brainstem-type LB disease samples, parahippocampal and cingulate cortex from limbic-type DLB patients contained significant amounts of ␣SYN monomers, dimers, and oligomers in the sarcosyl fractions. PK resistance confirmed the pathological nature of the ␣SYN recovered from the sarcosyl fractions of parahippocampal and cingulate cortex of limbic-type LB disease patients. However, the sarcosyl fractions from the frontal cortex of limbic-type LB disease patients barely contained any ␣SYN (Fig. 2A) .
PK-PET blots of the limbic-type LB disease cases revealed a similar distribution of PK resistant ␣SYN in the medulla (Fig. 2B) , substantia nigra (Fig. 2C) , and striatum with a predominant neuritic pathology (Fig. 2D) as seen in the brainstem-predominant LB disease cases (Fig.  1) . Additionally, these cases showed marked neuritic pathology and some LBs in the parahippocampal and cingulate gyrus (Fig. 2E, F) . No labeling was observed in the frontal cortex (Fig. 2G) .
Neocortical-Type LB Disease
In advanced LB disease stages, ␣-synucleinopathy spreads to the frontal cortex (25, 26) . Indeed, frontal cortex only form neocortical-type LB disease cases showed ␣SYN in the sarcosyl fractions, which was resistant to PK (Fig. 3A) . In addition, limbic regions such as the cingulate and parahippocampal gyrus contained PK-resistant ␣SYN in the sarcosyl fractions (Fig. 3A) . Moreover, striatal and medullary samples of neocortical-type LB disease cases contained PK-resistant ␣SYN in the sarcosyl fractions (Fig. 3A) , as was observed in limbic-type and brainstem-type LB disease patients (see above). All affected brain regions contained PK-resistant ␣SYN monomers, dimers, and oligomers/aggregates. Interestingly, sarcosyl fractions prepared from heavily affected tissue also contained PK-resistant ␣SYN species migrating with an apparent molecular mass of 25 kDa (Fig. 3A) . This material was reminiscent of the (␣SYN) p25 we have previously identified in LB disease patients based on its detergent insolubility (35) . In contrast, the soluble fractions from all brain regions of neocortical-type contained fully PK-labile ␣SYN monomer (Fig. 3A) , again with the medulla expressing relatively little ␣SYN compared to cerebral regions.
All cases with the neocortical subtype of LB disease showed numerous neuritic profiles and LBs in all examined brainstem and cortical regions including the frontal cortex (Fig. 3B-G) . The pathology in the limbic structures was much more pronounced than seen in the limbic-type LB disease cases.
Correlation of PK-Resistant ␣SYN Signal Intensities on PET Blots and Western Blots
Pathological ␣SYN immunoreactivity was quantitatively assessed by standard immunohistochemistry as well as on PK-PET blots and Western blots of brain samples from patients with brainstem-predominant (n ϭ 3), limbic (n ϭ 5), and neocortical (n ϭ 5) subtype LB disease (Table 2 ; Fig. 4 ). The medulla of all patients examined contained PK-resistant ␣SYN. Likewise, LB and LN pathology was detected on PK-PET blots from the substantia nigra of all patients examined. An important novel aspect is that detection of striatal ␣-synucleinopathy was facilitated with methods based on PK resistance compared to standard immunohistochemistry (Fig. 4) . There was practically no PK-resistant ␣SYN in the cortex of brainstem-predominant patients, some PK-resistant ␣SYN in the cingulate and parahippocampal cortex of limbic-type patients. Frontal cortex was most commonly affected in neocortical-type patients.
There was some variance in the extent of PK-resistant ␣SYN between different patients of the same subtype. The tissue used for immunohistochemistry and PK-PET blots and sarcosyl extraction were taken from contralateral hemispheres, which might contribute a systematic error. Nevertheless, there was a significant correlation between the distribution of pathological ␣SYN based on PK resistance and assessed with conventional immunohistochemistry. When the PK-resistant ␣SYN signal intensities scored on PK-PET blots were plotted against LB quantifications, there was a significant correlation (p Ͻ 0.02; ANOVA) between these parameters in all brain areas except for parahippocampal cortex, where the correlation between PK-PET blot signal intensity and LB count revealed only a trend (p ϭ 0.0789; ANOVA). The PK-resistant ␣SYN signal intensities determined on Western blots correlated significantly (p Ͻ 0.03; ANO-VA) with LB quantifications in all brain areas examined.
The signal intensities of PK-resistant ␣SYN on PET blots and Western blots were semiquantitatively rated and correlated with each other (not shown). ANOVA revealed that the correlation trend between the apparent amounts of PK-resistant ␣SYN on PET blots and Western blots in medulla and striatum did not reach the p Ͻ 0.05 significance level. This might reflect a greater sensitivity of the visual PK-PET blot technique to detect the diffuse neuritic pathology. In contrast, there was a significant correlation between the signal intensities of PK-resistant ␣SYN on Western blots and PK-PET blots in cortical samples (cingulate: p ϭ 0.0248; parahippocampal: p Ͻ 0.0055; frontal: p ϭ 0.0015; ANOVA). Thus, there was an increasingly significant positive correlation between PK-resistant ␣SYN signal intensities on PET blots and Western blots in the brain regions that become affected in the ascending course of ␣-synucleinopathy (brainstem/ striatum Ͻ limbic Ͻ neocortical). Western ϩ ϩ ϩ ϩ ϩ ϩ ϩ ϩ ϩ ϩ PET blot ϩ ϩ ϩ ϩ ϩ ϩ ϩ ϩ ϩ ϩ ϩ ϩ IHC ϩϩϩ ϩ 63 55 10 PK-resistant ␣SYN was detected on Western blots of sarcosyl extracts (Ϫ, none; Ϯ, faint; ϩ, weak; ϩϩ, moderate; ϩϩϩ, strong) and PET blots (LBs and LNs: Ϫ, none; Ϯ, single inclusion; ϩ, sparse; ϩϩ, moderate; ϩϩϩ, frequent). ␣SYN pathology obtained by standard immunohistochemistry was rated as LB counts in the cortical regions (cingulate: per gyrus; parahippocampal and frontal: per hemigyrus) and semiquantitative in the medulla and striatum (LBs and LNs: Ϫ, none; Ϯ, single inclusion; ϩ, sparse; ϩϩ, moderate; ϩϩϩ, frequent). Monoclonal 15G7 was used as anti-␣SYN in all assays.
DISCUSSION
Conventional histochemistry using hematoxylin and eosin and silver staining or immunostaining using antiubiquitin and anti-␣SYN demonstrated that neuropathology in the classical ␣-synucleinopathies proceeds from predilection sites in the brainstem through the limbic system into neocortical areas (25, 26) . Here we applied a recently developed histochemical technique that visualizes pathological ␣SYN with greatly enhanced contrast (12) . Specifically, PET blots prepared from brain sections are digested with PK effectively removing the abundant soluble ␣SYN, leaving behind only the pathological, insoluble ␣SYN. The pathological quality of PK-resistant ␣SYN was confirmed by correlation of the regional distribution of PET blot signal with established ␣-synucleinopathy stages. Insoluble, PK-resistant ␣SYN could be isolated from the same affected brain regions identified on PET blots. We have previously shown that in situ detection of PK-resistant ␣SYN on PET blots reveals more widespread pathology than standard epitope retrieval methods, including boiling in citric acid, formic acid treatment, or brief PK digest (36) . A limitation of the PK-PET blot is the low resolution, which hardly allows Tissue samples were taken from medulla (white bars), striatum (light grey bars), cingulate cortex (grey bars), parahippocampal cortex (dark grey bars), and frontal cortex (black). A: Brain sections were immunostained with 15G7 anti-␣SYN. Signal intensity in medulla and striatum was scored as follows: 0, none; 0.5, single inclusion; 1, sparse; 2, moderate; 3, frequent. LB counts are plotted for cortical samples. B: PK-PET blots were scored on the scale described above. C: PK-resistant, sarcosylextracted ␣SYN detected on Western blots was scored as follows: 0, none; 0.5, faint; 1, weak; 2, moderate; 3, strong. Results are mean values from 3 brainstem-predominant LB disease patients and 5 each limbic and neocortical subtype LB disease patients. Error bars indicate standard error. detection at the subcellular level. Nevertheless, detection of PK-resistant ␣SYN expands the methodological spectrum for ␣-synucleinopathies.
The regional distribution of PK-resistant ␣SYN followed the progression of Lewy pathology in brainstemtype, limbic-type, and neocortical-type patients. All LB disease patients had PK-resistant ␣SYN in the medulla. The amounts of PK-resistant, insoluble ␣SYN in the medulla increased with advancing ␣-synucleinopathy (Figs.  1-3) , consistent with the stages defined by Braak et al (26) . As expected, the parahippocampal and cingulate cortex contained insoluble, PK-resistant ␣SYN in limbictype LB disease patients, and the frontal cortex became affected in neocortical-type LB disease patients. Thus, the regional distribution of PK-resistant ␣SYN accurately reflects the disease stage of LB patients.
In addition to the outline of classical LB pathology, detection of PK-resistant ␣SYN is particularly useful for visualizing neuritic ␣SYN pathology that is often overshadowed by the great abundance of normal ␣SYN in the neuropil (12) . For example, axon terminal Lewy pathology in the striatum is hard to detect by conventional means, and has only recently been appreciated by the use of specific antibodies against oxidized ␣SYN (32). Here we provide clear biochemical evidence for pathological ␣SYN in the striatum, the target area of LB-containing nigral neurons. Although the amount of PK-resistant striatal ␣SYN was variable in our cohort of patients, it was consistently present. This finding suggests that ␣SYN fibrillization may occur at the site where ␣SYN is normally greatly enriched, that is, the synapse (34) .
Biochemical analysis allowed an assessment of the nature of ␣SYN recovered from affected brain areas of human patients. All cerebral brain regions examined expressed robust amounts of soluble ␣SYN regardless of disease state. The physiological ␣SYN was always monomeric. Medullary samples consistently contained lower levels of ␣SYN protein. Fibrillar ␣SYN can be enriched with sarcosyl extraction procotols (6, 37) . Sarcosyl extractable ␣SYN was detectable only in fractions prepared from brain samples affected by Lewy pathology. The molecular mass of the sarcosyl-extracted ␣SYN species both before and after PK digestion was consistent with monomers, dimers, and higher order oligomers/aggregates. Phospho-specific anti-␣SYN revealed that all PK-resistant ␣SYN species detectable by Western blot analysis and PK-PET blot were phosphorylated at serine-129 (data not shown). The recurrent presence of stable ␣SYN dimers in the pathological brain fractions provides in vivo support for the hypothesis that oxidative crosslinking of ␣SYN dimers is the rate-limiting step for aggregation (38, 39) . Clearly, interrupting the cascade of adverse events in ␣-synucleinopathy patients at the level of oxidative dimerization of ␣SYN using, for example, antioxidative drugs is a promising therapeutic target.
In addition, a 25-kDa ␣SYN species (␣SYN) p25 identified in the detergent-insoluble fractions of ␣-synucleinopathy patients (35) was also found here to be PK-resistant. (␣SYN) p25 is a strictly diagnostic band exclusively present in pathological fractions from affected brain samples of human patients. (␣SYN) p25 constitutes an authentic protein that is not a proteolytic product generated upon PK digestion, because it is present in insoluble fractions before enzymatic treatment. Two previous studies have described ␣SYN species (␣Sp22) with similar electrophoretic motility. O-glycosylation (40) or mono-ubiquitination (41) was proposed to account for the band shift of ␣Sp22. Unlike the highly soluble O-glycosylated ␣Sp22, (␣SYN) p25 is exclusively present in the sarcosyl fractions. The biochemical features of (␣SYN) p25 (insolubility and phosphorylation at serine-129) are reminiscent of mono-ubiquitinated ␣SYN (41). Alternatively, (␣SYN) p25 could correspond to stable dimers of N-terminally truncated ␣SYN.
The conversion of the normally highly soluble and proteinase-labile ␣SYN into insoluble, proteinase-resistant material is closely correlated with ␣-synucleinopathy progression. Because ␣SYN aggregates have the potential to inhibit the proteasome (42) , the development of proteinase-resistant ␣SYN might directly impair general protein turnover in the affected neurons. Indeed, decreased proteasomal function was found in PD substantia nigra (43) . Taken together, proteinase-resistant ␣SYN may not only be diagnostic, but also causative for ␣-synucleinopathies.
